WallStSmart

Akso Health Group ADR (AHG)vsEDAP TMS SA (EDAP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EDAP TMS SA generates 399% more annual revenue ($74.07M vs $14.84M). AHG leads profitability with a 0.0% profit margin vs -41.7%. EDAP earns a higher WallStSmart Score of 25/100 (F).

AHG

Avoid

16

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 6.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

EDAP

Avoid

25

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+18.0%)

Margin of Safety

+18.0%

Fair Value

$1.72

Current Price

$1.34

$0.38 discount

UndervaluedFair: $1.72Overvalued
EDAPUndervalued (+41.7%)

Margin of Safety

+41.7%

Fair Value

$8.41

Current Price

$4.31

$4.10 discount

UndervaluedFair: $8.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

EDAP0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AHG4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.70B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

EDAP4 concerns · Avg: 2.8/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Market CapQuality
$156.30M3/10

Smaller company, higher risk/reward

PEG RatioValuation
90.472/10

Expensive relative to growth rate

Return on EquityProfitability
-124.0%2/10

ROE of -124.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : EDAP

Revenue growth of 13.9% demonstrates continued momentum.

Bear Case : AHG

The primary concerns for AHG are Revenue Growth, EPS Growth, Market Cap.

Bear Case : EDAP

The primary concerns for EDAP are Price/Book, Market Cap, PEG Ratio.

Key Dynamics to Monitor

AHG profiles as a value stock while EDAP is a turnaround play — different risk/reward profiles.

EDAP carries more volatility with a beta of -0.10 — expect wider price swings.

EDAP is growing revenue faster at 13.9% — sustainability is the question.

AHG generates stronger free cash flow (3M), providing more financial flexibility.

Bottom Line

EDAP scores higher overall (25/100 vs 16/100) and 13.9% revenue growth. AHG offers better value entry with a 18.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and comprehensive patient care services. The company utilizes advanced health technologies to exploit burgeoning opportunities in telehealth and personalized medicine, supported by a strong emphasis on research and development. With a solid business model and a highly proficient workforce, Akso Health Group represents a compelling investment opportunity for institutional investors looking to capitalize on the dynamic changes within the healthcare industry.

Visit Website →

EDAP TMS SA

HEALTHCARE · MEDICAL DISTRIBUTION · USA

EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.

Want to dig deeper into these stocks?